

The Role of Orexin in the Effect of Electroacupuncture on Inflammatory Cytokines and Respiratory Regulations in a Rat Model of Smoke Induced Chronic Obstructive Pulmonary Disease: A Short Review

Zi-bing Liu^{1,2}, Wen-ye Geng^{3*} and Xin-fang Zhang¹

¹Physiology Department, College of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230038, Anhui Province, China

²Institute of Acupuncture and Meridian, College of Acupuncture and Osteology, Anhui University of Chinese Medicine, Hefei 230038, Anhui Province, China

³School of Pharmacy, Fudan University, Shanghai 200032, China

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation [1,2]. By 2020, COPD will rank third as the cause of death worldwide (it is sixth place in 1990), while the social burden of COPD will rank fifth (it is twelfth place in 1990). 90% of patients with COPD are smokers in Western countries, thus smoking has become one of the most important pathogenic factors in this disease [3-5]. COPD is thought to be caused by inflammation induced by inhaled smoke and particulates, conducting structural changes in airways and alveoli, resulting in airflow limitation. The pathology of COPD involves small airways and lung parenchyma, with chronic inflammation conducting luminal obstruction, thickening of the airway wall by increased deposition of matrix molecules and proliferation of mesenchymal cells, and narrowing of the airway by fibrosis, causing a decrease in lung function [1,6].

There are some different therapies for COPD. The anti-inflammatory therapy is one choice [7]. Targeting oxidative stress with antioxidants is likely to be beneficial in the treatment of the disease [8]. Acupuncture has been used as a clinical treatment for various diseases in traditional Chinese medicine for a long time including COPD. Although acupuncture can improve exercise capacity, respiratory function and respiratory muscle strength in patients with COPD its mechanisms are still unclear [9,10].

We first found that electroacupuncture (EA) could reduce lung injury in a COPD rat model, and the beneficial effects may be related to down-regulation of inflammatory cytokines and oxidants. And our further results suggested EA at Zusanli and Feishu improved lung function of rats with COPD and had an anti-inflammatory effect, which may be related to down regulation of OXA and its receptors [11-15].

The anti-inflammatory and antioxidant effects of EA

In our first paper we established the COPD model using male Sprague-Dawley rats exposed to cigarette smoke. The rats were randomly divided into four groups (control, sham, COPD, and COPD plus EA), and COPD model was evaluated by measuring pulmonary pathological changes and lung function. EA was applied to the acupuncture point Zusanli (ST36) for 30 min/d for 14 d in sham and COPD rats. Bronchoalveolar lavage fluid (BALF) was used to measure levels of tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), and malonaldehyde (MDA).

Compared with the control rats, COPD rats had significant changes in lung resistance (RL) and lung compliance (CL) (both $P < 0.01$), bronchi and bronchiole airway obstruction, and levels of MDA, TNF- α , and IL-1 β . Compared with the COPD rats, the COPD plus EA rats had decreased RL and increased CL, and reduced bronchi and bronchiole airway obstruction, while levels of TNF- α , IL-1 β , and MDA in BALF were lowered. However, TNF- α and IL-1 β levels of the EA group rats remained higher than those of the control group. EA at ST36 can reduce lung injury in a COPD rat model, related to down-regulation of

inflammatory cytokines. The clinical benefit of EA may from the anti-inflammatory and antioxidant effects [11].

The role of orexin in the mechanism of EA therapeutic action

Acupuncture at Zusanli (ST36) has anti-inflammatory and antioxidant effects but the mechanism of acupuncture's therapeutic action is not known. Neuropeptide orexins (OXs), discovered by Sakurai et al in 1998, are synthesized by the neurons in the lateral hypothalamic area of rats, and can be alternatively spliced into OXA and OXB [16]. OX neurons are located in the hypothalamus, but their fibers project to multiple brain sites, including the medullary respiratory center. Microinjection of OX can cause phrenic and hypoglossal nerve discharges, suggesting that OX is involved in the central regulation of respiratory activity [17,18]. We previously demonstrated respiratory activity in COPD rats with relatively high expression of OXA and its receptors in hypothalamus and medulla [19].

Orexin A and B levels in the lung tissue were detected by enzyme-linked immunosorbent assay. OX receptor mRNA levels and immunopositive cells were assessed with real-time polymerase chain reaction and immunohistochemical methods, respectively. The relationships among lung function, cell factors, and OX levels were analyzed by Pearson correlation analyses.

Compared with the control group, there were obvious increases in orexin A level, mRNA expressions of OX 1 type receptor (OXR1) and OX 2 type receptor (OXR2) in lung tissue; the integrative optical densities (IODs) of both receptors were greater in the COPD group. Orexin A, but not orexin B, levels in lung tissue also decreased, as did mRNA expression of OX1R and OX2R in lung tissue. Receptor IODs were also reduced after EA treatment. Furthermore, orexin A levels and ratio of forced expiratory volume in 0.3 s to forced vital capacity were strongly negatively correlated, and orexin A was positively correlated with TNF- α and IL-1 β [12].

So our results suggest that EA could regulate the orexin levels in the lung tissue and play the therapeutic action of anti-oxidant and anti-inflammation.

*Corresponding author: Wen-ye Geng, School of Pharmacy, Fudan University, China, Tel: +86-21-51980017; E-mail: drug@fudan.edu.cn

Received September 23, 2015; Accepted January 12, 2016; Published January 19, 2016

Citation: Liu Z, Geng W, Zhang X (2016) The Role of Orexin in the Effect of Electroacupuncture on Inflammatory Cytokines and Respiratory Regulations in a Rat Model of Smoke Induced Chronic Obstructive Pulmonary Disease: A Short Review. J Yoga Phys Ther 6: 225. doi:10.4172/2157-7595.1000225

Copyright: © 2016 Liu Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Acknowledgement

This work was supported by National Natural Science Foundation of China (NO.81072870; NO. 81102660; NO: 81373743) and Natural Science Foundation of Anhui Province in China (No. 1408085MH201)

References

1. Moghaddam SJ, Clement CG, De la Garza MM, Zou X, Travis EL, et al. (2008) *Haemophilus influenzae* lysate induces aspects of the chronic obstructive pulmonary disease phenotype. *Am J Respir Cell Mol Biol* 38: 629-638.
2. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, et al. (2004). The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 350: 2645-2653.
3. Sarir H, Henricks PA, van Houwelingen AH, Nijkamp FP, Folkerts G (2008) Cells, mediators and Toll-like receptors in COPD. *Eur J Pharmacol* 585: 346-353.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 176: 532-555.
5. Teramoto S (2007) 1. COPD pathogenesis from the viewpoint of risk factors. *Intern Med* 46: 77-79.
6. Barnes PJ (2004) Small airways in COPD. *N Engl J Med* 350: 2635-2637.
7. Gross NJ (2012) Novel anti-inflammatory therapies for COPD. *Chest* 142: 1300-1307.
8. Rahman I (2006) Antioxidant therapies in COPD. *Int J Chron Obstruct Pulmon Dis* 1: 15-29.
9. Neumeister W, Kuhlemann H, Bauer T, Krause S, Schultze- Werninghaus G, et al. (1999) Effect of acupuncture on quality of life, mouth occlusion pressures and lung function in COPD. *Med Klin (Munich)* 94: 106-109.
10. Suzuki M, Namura K, Ohno Y, Tanaka H, Egawa M, et al. (2008) The effect of acupuncture in the treatment of chronic obstructive pulmonary disease. *J Altern Complement Med* 14: 1097-1105.
11. Geng WY, Liu ZB, Song NN, Zhang GH, Jin WZ, et al. (2013) Effects of electroacupuncture at Zusanli (ST36) on inflammatory cytokines in a rat model of smoke-induced chronic obstructive pulmonary disease. *J Integr Med* 11: 213-219.
12. Zhang XF, Zhu J, Geng WY, Zhao SJ, Jiang CW, et al. (2014) Electroacupuncture at Feishu (BL13) and Zusanli (ST36) down-regulates the expression of orexins and their receptors in rats with chronic obstructive pulmonary disease. *J Integr Med* 12: 417-424.
13. Neumeister W, Kuhlemann H, Bauer T, Krause S, Schultze-Werninghaus G, (1999). Effect of acupuncture on quality of life, mouth occlusion pressures and lung function in COPD. *Med Klin (Munich)* 94: 106-109. German.
14. Lin YY, Wang YP, Lu HY, Guo XC, Liu X, et al. (2014) Plasma pharmacokinetics and lung distribution of tetrahydropalmatine after topical application of cold asthma recipe extract: Feishu (BL 13) versus non-Feishu acupoint. *J Ethnopharmacol* 153: 454-460.
15. Li R, Li WJ, Cai YN, Li ZG, Luo Q, et al. (2005) Effects of moxibustion at Feishu (BL13) and Gaohuang (BL43) on expression of TGF- β in the bleomycin-induced pulmonary fibrosis. *Zhongguo Zhen Jiu* 25: 790-792.
16. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573-585.
17. Young JK, Wu M, Manaye KF, Kc P, Allard JS, et al. (2005) Orexin stimulates breathing via medullary and spinal pathways. *J Appl Physiol* (1985) 98: 1387-1395.
18. Zhang W, Fukuda Y, Kuwaki T (2005) Respiratory and cardiovascular actions of orexin A in mice. *Neurosci Lett* 385: 131-136.
19. Liu ZB, Song NN, Geng WY, Jin WZ, Li L, et al. (2010) Orexin-A and respiration in a rat model of smoke-induced chronic obstructive pulmonary disease. *Clin Exp Pharmacol Physiol* 37: 963-968.